Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Delving into the recent phase 3 data from the ALIGN clinical trial of Novartis' atrasentan in patients with IgA Nephropathy.

Ticker(s): NVS, TVTX, CALT, KDNY

Who's the expert?

Institution: Columbia University

Professor of Medicine at Columbia University Medical Center and the Clinical Chief of the Nephrology Division at the New York Presbyterian Hospital.
Currently manages 10 patients with ANCA-Associated Vasculitis and ~40 patients with IgA Nephropathy (IgAN).
Clinical and research interests are in glomerular diseases and intensive care nephrology; PI for several multicenter studies and has served on DSMBs.

Interview Goal

This call will discuss the current standard of care and the potential of atrasentan, an oral endothelin A receptor antagonist being developed by Novartis for the treatment of IgA Nephropathy. The focus will be the recent phase 3 data from the ALIGN clinical trial of atrasentan in patients with IgAN.

Are You Interested In These Questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here to Access
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here to Access
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.